4-溴-2-氟苄胺盐酸盐 | 147181-08-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-溴-2-氟苄胺盐酸盐
• 中文别名: 3-溴-5-氟苄胺盐酸盐
• 英文名称: 4-bromo-2-fluorobenzylamine hydrochloride
• 英文别名: (4-bromo-2-fluorophenyl)methanamine hydrochloride；(4-Bromo-2-fluorophenyl)methanaminium chloride；(4-bromo-2-fluorophenyl)methylazanium;chloride
• CAS: 147181-08-6
• 化学式: C₇H₇BrFN*ClH
• mdl: MFCD00143266
• 分子量: 240.503
• InChiKey: RTQOFJWBJNVJEO-UHFFFAOYSA-N

物化性质

• 熔点：
  250-254 °C
• 稳定性/保质期：
  避氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  2.01
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 海关编码：
  29214200
• 危险类别：
  IRRITANT
• 安全说明：
  S24/25
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  保存方法：密封，存放在阴凉、通风和干燥的地方。

SDS

Name:	4-Bromo-2-Fluorobenzylamine Hydrochloride 99% (Titr.) Material Safety Data Sheet
Synonym:	None known.
CAS:	147181-08-6

Section 1 - Chemical Product MSDS Name: 4-Bromo-2-Fluorobenzylamine Hydrochloride 99% (Titr.) Material Safety Data Sheet
Synonym: None known.

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
147181-08-6	4-Bromo-2-Fluorobenzylamine Hydrochlor	99	unlisted

+++++
Hazard Symbols: None Listed.

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW The toxicological properties of this material have not been fully investigated. Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions. Provide ventilation.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 147181-08-6: Personal Protective Equipment
Eyes:
Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Powder
Color: white to pale yellow
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 249.00 - 254.00 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: soluble
Specific Gravity/Density:
Molecular Formula: C7H7BrFN.HCl
Molecular Weight: 240.50

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat, strong oxidants.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 147181-08-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Bromo-2-Fluorobenzylamine Hydrochloride - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA Not regulated as a hazardous material. IMO Not regulated as a hazardous material. RID/ADR Not regulated as a hazardous material.

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases: S 24/25 Avoid contact with skin and eyes. S 28A After contact with skin, wash immediately with plenty of water. S 37 Wear suitable gloves. S 45 In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). WGK (Water Danger/Protection) CAS# 147181-08-6: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 147181-08-6 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 147181-08-6 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 9/02/1997 Revision #5 Date: 3/18/2003 The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴-2-氟苄胺盐酸盐 在 氯化亚砜 、 氨 、 potassium carbonate 、 三乙胺 、 三氟乙酸 、 lithium hexamethyldisilazane 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 30.75h， 生成 4-(2-amino-2-oxoethyl)-2-<(4-bromo-2-fluorophenyl)methyl>-1,2,3,4-tetrahydro-1,3-dioxo-4-isoquinolinecarboxylic acid menthyl ester
  参考文献：
  名称：

  衍生自异喹啉-1,3-二酮的新型螺琥珀酰亚胺醛糖还原酶抑制剂：2-[（（4-溴-2-氟苯基）甲基] -6-氟螺[异喹啉-4（1H），3'-吡咯烷] -1,2 '，3,5'（2H）-同质子和同类物。1。

  摘要：

  在糖尿病性高血糖症期间形成的高浓度血浆葡萄糖会迅速转化为组织中的葡萄糖水平高，而葡萄糖的摄取与胰岛素无关。在这些包括晶状体，视网膜，神经和肾脏的组织中，过量的葡萄糖进入山梨醇（多元醇）途径。该途径中的第一个酶，醛糖还原酶，将葡萄糖还原为山梨糖醇。据信糖尿病引起的通过多元醇途径的葡萄糖通量增加在糖尿病某些慢性并发症的发展中起重要作用。抑制醛糖还原酶活性并阻止葡萄糖通过多元醇途径的化合物可预防糖尿病动物的神经病变和肾病的发展，并中断糖尿病患者的神经病变的进展。在这里，我们描述了新型醛糖还原酶抑制剂的制备和表征。基于异喹啉-1,3-二酮构架，对这些螺[isoquinoline-4（1H），3'-吡咯烷] -1,2'，3,5'-（2H）-四氢萘进行了体外评估使用部分纯化的牛晶状体醛糖还原酶制剂抑制甘油​​醛还原的能力，以及体内抑制半乳糖喂养的大鼠晶状体和坐骨神经中半乳糖醇积累的能力。在异喹啉-1,

  DOI：

  10.1021/jm00039a017
• 作为产物：
  描述：

  4-溴-2-氟苄醇 在 sodium azide 、 三乙胺 、 三苯基膦 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 45.5h， 生成 4-溴-2-氟苄胺盐酸盐
  参考文献：
  名称：

  可持续的有机磷催化施陶丁格还原

  摘要：

  已经开发出一种高效且可持续的Staudinger催化还原方法，用于以优异的产率将有机叠氮化物转化为胺。该反应对优异的官能团具有极好的官能团耐受性，这些官能团否则容易还原，例如砜，酯，酰胺，酮，腈，烯烃和苄基醚。通过使用PMHS，CPME和缺少柱色谱法可以举例说明反应的绿色性质。

  DOI：

  10.1039/c8gc02136h
• 作为试剂：
  描述：

  4-溴-2-氟苄胺盐酸盐 、 R-(-)-3-ethoxycarbonyl-3-(2-(trichloroacetyl)pyrrol-1-yl)pyrrolidin-2,5-dione 在 4-溴-2-氟苄胺盐酸盐 作用下， 以43.6的产率得到雷尼司他
  参考文献：
  名称：

  Tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3'-pyrrolidine derivatives,

  摘要：

  该文翻译如下： Tetrahydropyrrolo [1,2-a] pyrazine-4-spiro-3'-pyrrolidine 衍生物的化学式如下：##STR1## 其中 R.sup.1 和 R.sup.2 独立地表示氢、卤素、三氟甲基、具有1至6个碳原子的烷基、具有1至6个碳原子的烷氧基或硝基，而 R.sup.3 表示氢、卤素或具有1至6个碳原子的烷基，以及其制备过程和药学上可接受的盐，以及含有它们的制药组合物。这些化合物及其盐表现出出色的醛固酮还原酶抑制活性，可用于预防和治疗糖尿病并发症。

  公开号：

  US05258382A1

文献信息

• [EN] IMIDAZO [1, 2 - B] PYRIDAZINE - BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF<br/>[FR] COMPOSÉS À BASE D'IMIDAZO [1, 2-B] PYRIDAZINE, COMPOSITIONS LES COMPRENANT ET UTILISATIONS DE CEUX-CI
  申请人：LEXICON PHARMACEUTICALS INC

  公开号：WO2013134219A1

  公开（公告）日：2013-09-12

  Imidazo[1,2-b]pyridazine-based compounds of the formula (I): are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.

  基于咪唑并[1,2-b]吡啶嗪的化合物的公式（I）被披露，其中R1、R2和R3在此处被定义。还披露了包含这些化合物的组合物以及它们用于治疗、管理和/或预防由适配器相关激酶1活性介导的疾病和紊乱的方法。
• Catalytic Staudinger Reduction at Room Temperature
  作者：Danny C. Lenstra、Joris J. Wolf、Jasmin Mecinović

  DOI：10.1021/acs.joc.9b00831

  日期：2019.5.17

  catalytic Staudinger reduction at room temperature that enables the preparation of a structurally diverse set of amines from azides in excellent yields. The reaction is based on the use of catalytic amounts of triphenylphosphine as a phosphine source and diphenyldisiloxane as a reducing agent. Our catalytic Staudinger reduction exhibits a high chemoselectivity, as exemplified by reduction of azides

  我们报道了在室温下有效的Staudinger催化还原反应，该反应能够以优异的收率从叠氮化物制备结构多样的胺。该反应基于催化量的三苯基膦作为膦源和二苯基二硅氧烷作为还原剂的使用。我们的Staudinger催化还原具有很高的化学选择性，例如叠氮化物相对于其他常见官能团（包括腈，烯烃，炔烃，酯和酮）的还原。
• Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complications
  作者：Michael C. Van Zandt、Evelyn O. Sibley、Erin E. McCann、Kerry J. Combs、Brenda Flam、Diane R. Sawicki、Al Sabetta、Anne Carrington、Janet Sredy、Eduardo Howard、Andre Mitschler、Alberto D. Podjarny

  DOI：10.1016/j.bmc.2004.07.062

  日期：2004.11

  Recent efforts to identify treatments for chronic diabetic complications have resulted in the discovery of a novel series of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid aldose reductase inhibitors. The compound class features a core template that utilizes an intramolecular hydrogen bond to position the key structural elements of the pharmacophore in a conformation, which promotes

  最近鉴定慢性糖尿病并发症的治疗方法的努力导致发现了一系列新的高效和选择性的（2-芳基氨基甲酰基-苯氧基）乙酸醛糖还原酶抑制剂。化合物类别的特征是核心模板，该模板利用分子内氢键将药效基团的关键结构元件定位在构象中，从而促进了高结合亲和力。铅候选物，例如40，5-氟-2-（4-溴-2-氟-苄硫代氨基甲酰基）-苯氧基乙酸，抑制醛糖还原酶，IC（50）为30 nM，而对醛还原酶的活性低1100倍，是一种与活性醛解毒有关的酶。另外，实施例40在4天STZ诱导的糖尿病大鼠模型中以31mg / kg / d po的ED（50）降低了神经山梨糖醇水平。
• PROCESS FOR PRODUCING OPTICALLY ACTIVE SUCCINIMIDE DERIVATIVES AND INTERMEDIATES THEREOF
  申请人：Kyowa Hakko Bio Co., Ltd.

  公开号：US20140099681A1

  公开（公告）日：2014-04-10

  A process for producing optically active succinimide derivatives as key intermediates of (3R)-2′-(4-bromo-2-fluorobenzyl)spiropyrrolidine-3,4′(1′H)-pyrrolo[1,2-a]pyrazine}-1′,2,3′,5(2′H)-tetraone, which comprises the following reaction steps.

  生产(3R)-2′-(4-溴-2-氟苯基)螺吡咯啉-3,4′(1′H)-吡咯并[1,2-a]吡嗪}-1′,2,3′,5(2′H)-四酮的光学活性琥珀酰亚胺衍生物作为关键中间体的方法，包括以下反应步骤。
• Facile synthesis of novel spiro[azetidine-2,4′(1′<i>H</i>)-isoquinoline-1′,3′,4(2′<i>H</i>)-triones]
  作者：Michael S. Malamas

  DOI：10.1002/jhet.5570310254

  日期：1994.3

  A convenient general method for the synthesis of a new heterocycle, spiro[azetidine-2,4′(1′H)-iso-quinoline-1′,3′,4(2′H)-trione] is described. The key intermediate 2 was prepared by direct halogenation of position-4 of acid 3 with thionyl chloride, and subsequent treatment of the generated 4-Cl, 4-acetyl chloride 11 with a THF/NH3 solution at low temperature.

  为一个新的杂环，螺合成的方便的一般方法[氮杂环丁烷-2,4' - （1' ħ） -异喹啉-1'，3'，4（2' ħ） -三酮]进行说明。通过用亚硫酰氯直接卤化酸3的4位，然后在低温下用THF / NH 3溶液处理生成的4-Cl，4-乙酰氯11，来制备关键中间体2。